Development of an RBD-Fc fusion vaccine for COVID-19

Abstract excerpt

Although the global pandemic of SARS-CoV-2 has passed, there are still regional outbreaks that continue to jeopardize human health. Hence, there is still a great deal of interest in developing an efficient vaccine that can quickly and effectively prevent reemerging outbreaks of SARS-CoV-2. Delta variant was once a dominant strain in the world in 2021, and we first constructed a recombinant RBDdelta-Fc fusion...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bacterial Infections and Vaccines
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to SARS-CoV-2 and COVID-19 Research